Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.
Location: SIMR (Sacramento/Valley Area, Roseville, and Auburn)
Please contact: SIMR@sutterhealth.org about Metastatic (AstraZeneca D533AC00001 MONETTE)
Principal Investigator
Co-Investigator(s)
Sivakumar Reddy, M.D., Jaspreet K Dhillon, Medical Oncologist, Kristie A. Bobolis, M.D., Brian K. Kim, M.D, Vijay Suhag, M.D., Rajeswari Chellappah, M.D., Dron Gauchan, MD, Kristin N. Arreola, M.D.